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Introduction
Recent data suggest an important role of zidovudine
(ZDV) and interferon-a (IFN-a)i ni m p r o v i n gr e s p o n s e
rates and survival in acute ATLL. Treatment of chronic
ATLL with ZDV/IFN-a alone has recently been asso-
ciated with 100% survival beyond five years.
Methods
Retrospective analysis of patients with acute and chronic
ATLL treated with ZDV/IFN-a first line. Response was
assessed one month from the start of treatment using
total lymphocyte and CD4 count, HTLV-1 proviral load
(PVL) and clonal analysis (in house method).
Results
Acute ATLL: response rate 33% (1 CR, 2 PR). Median
overall survival (OS) 3 months (range 3-8).
Chronic ATLL: response rate 100% (4 CR, 1 PR). Median
OS 20 months (range 9-73). In chronic ATLL these pro-
longed responses were observed despite lower dose therapy.
Two patients, showed 10-fold reductions in PVL which
occurred more than 1 year after haematological CR. All
patients remain in remission at time of analysis. Clonality
studies demonstrated a dominant clone at base line with
emergence of a polyclonal pattern after viral load reduction.
Discussion
The complete response in one patient with acute ATLL
supports the recent observation that ZDV/IFN-a is
effective as first line treatment in some patients.
The significant reduction in PVL and late emergence
of a polyclonal integration pattern suggest benefit from
prolonged ZDV/IFN-a therapy in chronic ATLL and the
utility of both PVL and clonal analysis as a test of the
efficacy of novel treatment regimes.
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